Table 1 Background of interviewed stakeholders
From: Stakeholders’ views on the ethical challenges of pragmatic trials investigating pharmaceutical drugs
Respondent characteristics | Number |
|---|---|
34 | |
Sex | |
Male | 21 |
Female | 13 |
IMI GetReal member | |
Yes | 6 |
No | 28 |
Country of professional residence | |
The Netherlands | 9 |
United Kingdom | 8 |
Germany | 5 |
France | 2 |
Belgium | 1 |
Denmark | 1 |
United States | 7 |
Israel | 1 |
Experience with pragmatic trials | |
Yes | 23 |
No | 11 |
Stakeholder group | |
Pharmaceutical industry | 16 |
Academia/nonprofit research institutions | 6 |
Contract research organizations (CROs) | 4 |
Health Technology Assessment (HTA) | 2 |
Regulatory bodies | 2 |
Patient representatives | 2 |
Clinicians | 1 |
Health insurers | 1 |